

MASSFELDER et al.
Appl. No. 10/520,085
January 10, 2008
AMENDMENT AFTER FINAL REJECTION

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-16. (Cancelled)

17. (Currently Amended) A method for treating a kidney cancer comprising the administration to a subject of an effective dose of a PTHrP antagonist for inhibiting or decreasing a tumor growth or a pharmaceutical composition containing it, said PTHrP antagonist being an anti-PTHrP antibody directed against an intermediate region of PTHrP.

18. (Previously Presented) Method according to claim 17, wherein said subject is a human subject.

19. (Previously Presented) Method according to claim 17, wherein said kidney cancer is selected from the group consisting of papillary carcinoma (chromophiles), chromophobe cell carcinoma, Bellini carcinoma and unclassified renal cell carcinomas.

20. (Previously Presented) Method according to claim 19, wherein said kidney cancer is clear cell carcinoma (CCC).

Claim 21. (Cancelled)

Claims 22. (Cancelled)

23. (Previously Presented) Method according to claim 17, wherein the kidney cancer is a solid malignant tumour.

MASSFELDER et al.

Appl. No. 10/520,085

January 10, 2008

AMENDMENT AFTER FINAL REJECTION

24. (Previously Presented) Method according to claim 17, wherein the PTHrP antagonist is a compound binding the PTHrP receptor and inhibiting partially or totally a binding of PTHrP to its receptor.

25. (Previously Presented) Method according to claim 24, wherein the PTHrP antagonist is a PTHrP receptor antagonist.

26. (Previously Presented) Method according to claim 25, wherein the PTHrP antagonist is a PTHrP competitive antagonist.

Claims 27-30. (Cancelled)

31. (Previously Presented) Method according to claim 17, wherein the PTHrP antagonist is a compound binding a ligand of the PTHrP receptor, and inhibiting partially or totally a binding of PTHrP to its receptor.

Claim 32. (Cancelled)

33. (Previously Presented) Method according to claim 17, wherein the PTHrP antagonist is a humanised anti-PTHrP antibody.

34. (Previously Presented) Method according to claim 17, wherein the anti-PTHrP antibody is selected from a humanised antibody, a human antibody, a chimeric antibody, an antibody obtained from a hybridoma and a fragment thereof and a modified form of said fragment.

AMENDMENT AFTER FINAL REJECTION

35. (Previously Presented) Method according to claim 17, wherein the anti-PTHrP antibody is a polyclonal or monoclonal antibody.

Claim 36. (Cancelled)

Claim 37. (Cancelled)

38. (new) A method for treating a kidney cancer comprising the administration to a subject of an effective dose of a PTHrP antagonist for inhibiting or decreasing a tumor growth or a pharmaceutical composition containing it, said PTHrP antagonist being an anti-PTHrP antibody directed against a carboxy terminal region of PTHrP.

39. (new) Method according to claim 38, wherein said subject is a human subject.

40. (new) Method according to claim 38, wherein said kidney cancer is selected from the group consisting of papillary carcinoma (chromophiles), chromophobe cell carcinoma, Bellini carcinoma and unclassified renal cell carcinomas.

41. (new) Method according to claim 40, wherein said kidney cancer is clear cell carcinoma (CCC).

42. (new) Method according to claim 38, wherein the kidney cancer is a solid malignant tumour.

43. (new) Method according to claim 38, wherein the PTHrP antagonist is a compound binding the PTHrP receptor and inhibiting partially or totally a binding of PTHrP to its receptor.

AMENDMENT AFTER FINAL REJECTION

44. (new) Method according to claim 43, wherein the PTHrP antagonist is a PTHrP receptor antagonist.

45. (new) Method according to claim 44, wherein the PTHrP antagonist is a PTHrP competitive antagonist.

46. (new) Method according to claim 38, wherein the PTHrP antagonist is a compound binding a ligand of the PTHrP receptor, and inhibiting partially or totally a binding of PTHrP to its receptor.

47. (new) Method according to claim 38, wherein the PTHrP antagonist is a humanised anti-PThrP antibody.

48. (new) Method according to claim 38, wherein the anti-PThrP antibody is selected from a humanised antibody, a human antibody, a chimeric antibody, an antibody obtained from a hybridoma and a fragment thereof and a modified form of said fragment.

49. (new) Method according to claim 38, wherein the anti-PThrP antibody is a polyclonal or monoclonal antibody.

50. (new) The method according to claim 17, wherein the intermediate region of PTHrP is from 38 to 94/95/101 of PTHrP.

51. (new) The method according to claim 17, wherein the anti-PThrP antibody is an anti-PThrP (34-53) antibody.

MASSFELDER et al.
Appl. No. 10/520,085
January 10, 2008
AMENDMENT AFTER FINAL REJECTION

52. (New) The method according to claim 38, wherein the C-terminal region of PTHrP is from 107 to 139 of PTHrP.